600 related articles for article (PubMed ID: 30572031)
1. Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.
Yatabe Y; Dacic S; Borczuk AC; Warth A; Russell PA; Lantuejoul S; Beasley MB; Thunnissen E; Pelosi G; Rekhtman N; Bubendorf L; Mino-Kenudson M; Yoshida A; Geisinger KR; Noguchi M; Chirieac LR; Bolting J; Chung JH; Chou TY; Chen G; Poleri C; Lopez-Rios F; Papotti M; Sholl LM; Roden AC; Travis WD; Hirsch FR; Kerr KM; Tsao MS; Nicholson AG; Wistuba I; Moreira AL
J Thorac Oncol; 2019 Mar; 14(3):377-407. PubMed ID: 30572031
[TBL] [Abstract][Full Text] [Related]
2. Automated chromogenic multiplexed immunohistochemistry assay for diagnosis and predictive biomarker testing in non-small cell lung cancer.
Ilie M; Beaulande M; Hamila M; Erb G; Hofman V; Hofman P
Lung Cancer; 2018 Oct; 124():90-94. PubMed ID: 30268486
[TBL] [Abstract][Full Text] [Related]
3. The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases.
Thunnissen E; Borczuk AC; Flieder DB; Witte B; Beasley MB; Chung JH; Dacic S; Lantuejoul S; Russell PA; den Bakker M; Botling J; Brambilla E; de Cuba E; Geisinger KR; Hiroshima K; Marchevsky AM; Minami Y; Moreira A; Nicholson AG; Yoshida A; Tsao MS; Warth A; Duhig E; Chen G; Matsuno Y; Travis WD; Butnor K; Cooper W; Mino-Kenudson M; Motoi N; Poleri C; Pelosi G; Kerr K; Aisner SC; Ishikawa Y; Buettner RH; Keino N; Yatabe Y; Noguchi M
J Thorac Oncol; 2017 Feb; 12(2):334-346. PubMed ID: 27998793
[TBL] [Abstract][Full Text] [Related]
4. The impact of immunohistochemistry on the classification of lung tumors.
Pelosi G; Scarpa A; Forest F; Sonzogni A
Expert Rev Respir Med; 2016 Oct; 10(10):1105-21. PubMed ID: 27617475
[TBL] [Abstract][Full Text] [Related]
5. The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs.
Micke P; Mattsson JS; Djureinovic D; Nodin B; Jirström K; Tran L; Jönsson P; Planck M; Botling J; Brunnström H
J Thorac Oncol; 2016 Jun; 11(6):862-72. PubMed ID: 26872818
[TBL] [Abstract][Full Text] [Related]
6. [Contribution of immunohistochemistry to the management of lung cancer: from morphology to diagnosis and treatment].
Antoine M
Rev Pneumol Clin; 2007 Jun; 63(3):183-92. PubMed ID: 17675942
[TBL] [Abstract][Full Text] [Related]
7. ΔNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach.
Pelosi G; Fabbri A; Bianchi F; Maisonneuve P; Rossi G; Barbareschi M; Graziano P; Cavazza A; Rekhtman N; Pastorino U; Scanagatta P; Papotti M
J Thorac Oncol; 2012 Feb; 7(2):281-90. PubMed ID: 22071786
[TBL] [Abstract][Full Text] [Related]
8. Rapid Immunohistochemistry With Thyroid Transcription Factor-1 for Pulmonary Adenocarcinoma.
Konno H; Saito H; Nanjo H; Hiroshima Y; Kurihara N; Fujishima S; Atari M; Sato Y; Motoyama S; Nakamura R; Akagami Y; Minamiya Y
Ann Thorac Surg; 2017 Aug; 104(2):471-476. PubMed ID: 28527968
[TBL] [Abstract][Full Text] [Related]
9. [Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].
Scheel AH; Dietel M; Heukamp LC; Jöhrens K; Kirchner T; Reu S; Rüschoff J; Schildhaus HU; Schirmacher P; Tiemann M; Warth A; Weichert W; Fischer RN; Wolf J; Büttner R
Pathologe; 2016 Nov; 37(6):557-567. PubMed ID: 27510417
[TBL] [Abstract][Full Text] [Related]
10. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.
Osmani L; Askin F; Gabrielson E; Li QK
Semin Cancer Biol; 2018 Oct; 52(Pt 1):103-109. PubMed ID: 29183778
[TBL] [Abstract][Full Text] [Related]
11. Various Antibody Clones of Napsin A, Thyroid Transcription Factor 1, and p40 and Comparisons With Cytokeratin 5 and p63 in Histopathologic Diagnostics of Non-Small Cell Lung Carcinoma.
Tran L; Mattsson JS; Nodin B; Jönsson P; Planck M; Jirström K; Botling J; Micke P; Brunnström H
Appl Immunohistochem Mol Morphol; 2016 Oct; 24(9):648-659. PubMed ID: 26447895
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and Predictive Immunohistochemistry for Non-Small Cell Lung Carcinomas.
Hung YP; Sholl LM
Adv Anat Pathol; 2018 Nov; 25(6):374-386. PubMed ID: 30188361
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors.
McCluggage WG; Young RH
Semin Diagn Pathol; 2005 Feb; 22(1):3-32. PubMed ID: 16512597
[TBL] [Abstract][Full Text] [Related]
14. Update on Immunohistochemical Analysis in Breast Lesions.
Peng Y; Butt YM; Chen B; Zhang X; Tang P
Arch Pathol Lab Med; 2017 Aug; 141(8):1033-1051. PubMed ID: 28574279
[TBL] [Abstract][Full Text] [Related]
15. Antigenic phenotype of lung carcinomas: usual spectrum of distribution of thyroid transcription factor-1, cytokeratin 7, cytokeratin 20, and neuron specific enolase--basic immunohistochemical study of 21 cases.
Kostovski M; Petrushevska G
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2014; 35(1):199-207. PubMed ID: 24798606
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
Hirsch FR; McElhinny A; Stanforth D; Ranger-Moore J; Jansson M; Kulangara K; Richardson W; Towne P; Hanks D; Vennapusa B; Mistry A; Kalamegham R; Averbuch S; Novotny J; Rubin E; Emancipator K; McCaffery I; Williams JA; Walker J; Longshore J; Tsao MS; Kerr KM
J Thorac Oncol; 2017 Feb; 12(2):208-222. PubMed ID: 27913228
[TBL] [Abstract][Full Text] [Related]
17. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
[TBL] [Abstract][Full Text] [Related]
18. p40 & thyroid transcription factor-1 immunohistochemistry: A useful panel to characterize non-small cell lung carcinoma-not otherwise specified (NSCLC-NOS) category.
Walia R; Jain D; Madan K; Sharma MC; Mathur SR; Mohan A; Iyer VK; Kumar L
Indian J Med Res; 2017 Jul; 146(1):42-48. PubMed ID: 29168459
[TBL] [Abstract][Full Text] [Related]
19. Immunostaining in lung cancer for the clinician. Commonly used markers for differentiating primary and metastatic pulmonary tumors.
Carney JM; Kraynie AM; Roggli VL
Ann Am Thorac Soc; 2015 Mar; 12(3):429-35. PubMed ID: 25700114
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of classifying poorly differentiated non-small cell lung carcinoma biopsies with commonly used lung carcinoma markers.
Zachara-Szczakowski S; Verdun T; Churg A
Hum Pathol; 2015 May; 46(5):776-82. PubMed ID: 25776027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
